|Bid||175.57 x 100|
|Ask||179.95 x 9600|
|Day's range||176.60 - 179.80|
|52-week range||160.07 - 256.80|
|PE ratio (TTM)||N/A|
|Earnings date||6 Feb 2018|
|Forward dividend & yield||2.80 (1.59%)|
|1y target est||222.81|
Teva Pharmaceutical (TEVA) receives approval from the FDA for label expansion of its leukemia drug, Trisenox, in first-line setting.
OKLAHOMA CITY (AP) — The first trial date has been set for a lawsuit by a state against pharmaceutical companies over the opioid epidemic, according to Oklahoma's attorney general.
Pershing Square Holdings, the hedge fund operated by noted activist investor Bill Ackman, on Wednesday announced it was slashing its management fees, a move related to the settlement of two class-action ...
COLUMBUS, Ohio (AP) — A federal judge on Tuesday set a goal of doing something about the nation's opioid epidemic this year, while noting the drug crisis is "100 percent man-made."
Allergan (AGN) announces weaker-than-expected sales outlook for 2018. A generic version of Restasis is expected to be launched in Q2.
The biosimilar space was much in focus as the FDA approved a few biosimilars for key blockbuster drugs. We expect investor focus on the same in 2018 as well.
In a relatively slow week, Allergan's (AGN) job cut announcement remained the key highlight while Pfizer's collaboration agreements with Sangamo and Arvinas were also in focus.
Allergan (AGN) is laying off over 1,000 employees as part of a cost-cutting and restructuring program as it faces potential loss of exclusivity for some of its key products in 2018.
Executives of Pershing Square Capital Management and Valeant Pharmaceuticals International Inc. were ordered to come to court to defend the fairness of the $290 million settlement of an insider-trading ...
NEW YORK (AP) — Allergan will eliminate about 5.5 percent of its workforce as part of a cost-cutting move while it prepares for generic competition on several lucrative drugs.
Allergan plans to cut more than 1,000 jobs as part of its cost-cutting efforts, the company said in a government filing on Wednesday.
Allergan PLC plans to lay off 1,000 employees and eliminate about 400 open positions in an effort to meet 2018 non-GAAP performance net income per share goals, according to a financial filing posted on ...
Valeant (VRX) and Pershing Square decided to resolve the claims of the long standing Allergan lawsuit for $290 million. Valeant will now pay 33% of the costs, down from the previous agreement of 60%.
Activist investor Bill Ackman’s Pershing Square Holdings Ltd. and Valeant Pharmaceuticals International Inc. agreed to pay $290 million to settle investor claims that they engaged in insider trading in ...
Valeant Pharmaceuticals International Inc. said Friday that all parties in the Allergan Inc. shareholder securities litigation have agreed to resolve the claims that total $290 million, subject to court ...
Although it's been a relatively slow week, two acquisition deals were announced with Roche (RHHBY) saying it will acquire Ignyta while Mallinckrodt will buy Sucampo.
Intercept (ICPT) had a tough time in 2017 after news of death were out related to lead drug's Ocaliva's dosing. We do not expect a phenomenal revival in 2018 either.
For 3Q17, Sanofi reported revenues of 9.05 billion euros—a 4.7% YoY (year-over-year) rise in operating revenues, compared with 9.03 billion in 3Q16.